Tysabri and PML: What Symptoms to Document in Your Medical Record

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Targeted Risk Assessment

If you or a loved one has taken Tysabri and are now experiencing neurological changes like confusion, vision problems, or weakness, documenting these symptoms promptly is critical. For decades, pharmacovigilance research has established that early detection of Progressive Multifocal Leukoencephalopathy (PML) can significantly impact outcomes. This page outlines the key symptoms to monitor and how to maintain a thorough medical record for follow-up care.

Tysabri and PML: Clinical Evidence and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration has assigned a boxed warning to Tysabri regarding this risk, emphasizing that healthcare professionals must monitor patients for any new signs or symptoms suggestive of PML and withhold dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The condition can be rapidly debilitating, and treatment options are limited, often focusing on immune reconstitution. In clinical trials, PML occurred in three patients who received Tysabri: two among 1,869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1,043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for multiple sclerosis, but it also impairs immune surveillance against JC virus. In the absence of adequate T-cell monitoring, JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Risk factors for PML in Tysabri-treated patients include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy.

Legal and Settlement Considerations for Tysabri-Related PML

Regarding the adequacy of warnings, the prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML and the need for monitoring. The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires prescribers, patients, and pharmacies to enroll and adhere to specific safety protocols (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, lawsuits have been filed by patients who developed PML, alleging that the warnings were insufficient or that the risks were not adequately communicated. Settlement criteria in such cases often consider factors such as the timing of diagnosis, severity of disability, duration of Tysabri use, presence of anti-JCV antibodies, and prior immunosuppressant exposure. The timeline between exposure and documented harm is critical: PML can develop months to years after starting Tysabri, and early detection through MRI and JC virus testing may improve outcomes, though prognosis remains poor. For affected patients, settlement-related considerations include the extent of neurological impairment, medical expenses, lost earnings, and pain and suffering. Legal claims may argue that the manufacturer failed to provide adequate warnings about PML risk, especially for patients without identified risk factors. However, the boxed warning and TOUCH program represent significant regulatory efforts to mitigate risk. Patients who develop PML after Tysabri treatment may be eligible for compensation through litigation or settlement, depending on individual circumstances and jurisdictional laws. In summary, Tysabri is associated with a substantial risk of PML, a severe and often fatal brain infection. The drug's labeling includes explicit warnings and a restricted distribution program, but cases continue to occur. Understanding the clinical presentation, risk factors, and mechanistic pathways is essential for healthcare providers and patients. For those affected, legal and settlement options may provide financial relief, though outcomes vary based on evidence of warning adequacy and individual case details.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing forms of multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of blocking immune cell migration into the brain, which impairs viral surveillance.

What are the settlement criteria for Tysabri-related PML lawsuits?

Settlement criteria typically include the timing of PML diagnosis, severity of neurological disability, duration of Tysabri use, presence of anti-JCV antibodies, prior immunosuppressant exposure, and evidence of inadequate warnings. Each case is evaluated individually based on these factors and jurisdictional laws.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.